ReviewOncoTargets and therapy2016
Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Needle-injected wireless light-emitting device for 5-aminolevulinic acid-mediated photodynamic therapy of breast cancer.Biomedical optics express · 2026Article
- A novel near-infrared II viscosity-responsive probe for surgical fluorescence guidance: laboratory investigation in a murine subcutaneous glioma model.Frontiers in oncology · 2026Article
- Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence andNeuro-oncology practice · 2023Article
- Optimization of novel exoscopic blue light filter during fluorescence-guided resection of Glioblastoma.Journal of neuro-oncology · 2023Article
- EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.Theranostics · 2021Article
- Heterogeneity Matters: Different Regions of Glioblastoma Are Characterized by Distinctive Tumor-Supporting Pathways.Cancers · 2020Article
- 5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.Ontario health technology assessment series · 2020Article
- Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy.British journal of cancer · 2019Article
- Surgery for Malignant Brain Gliomas: Fluorescence-Guided Resection or Functional-Based Resection?Frontiers in surgery · 2019Article
- Fluorescence-guided surgery with aminolevulinic acid for low-grade gliomas.Journal of neuro-oncology · 2019Review
- Challenges and opportunities in clinical translation of biomedical optical spectroscopy and imaging.Journal of biomedical optics · 2018Review
- With a Little Help from My Friends: The Role of Intraoperative Fluorescent Dyes in the Surgical Management of High-Grade Gliomas.Brain sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgical resection is typically the first line of treatment for gliomas. However, the neurosurgeon faces a major challenge in achieving maximal resection in high-grade gliomas as these infiltrative tumors make it difficult to discern tumor margins from normal brain with conventional white-light microscopy alone. To aid in resection of these infiltrative tumors, fluorescence-guided surgery has gained much popularity in intraoperative visualization of malignant gliomas, with 5-aminolevulinic acid (5-ALA) leading the way. First introduced in an article in Neurosurgery, 5-ALA has since become a safe, effective, and inexpensive method to visualize and improve resection of gliomas. This has undoubtedly led to improvements in the clinical course of patients as demonstrated by the increased overall and progression-free survival in patients with such devastating disease. This literature review aims to discuss the major studies and trials demonstrating the clinical utility of 5-ALA and its ability to aid in complete resection of malignant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.